Study of Olutasidenib and Ziftomenib for AML with IDH1 and NPM1 Mutations
This study is testing two oral medications, olutasidenib and ziftomenib, for people with acute myeloid leukemia (AML) that has come back or is not responding to treatment. To join, your AML must have specific changes (mutations) in the IDH1 and NPM1 genes. The first part of the study will find the best dose of these two drugs when given together. The second part will see how well this combination controls the disease. Researchers will also be looking closely at the safety and any side effects you might experience. The study aims to enroll 20 participants, but its current status is unclear.
- Study design
- This is an interventional study, meaning you will receive a specific treatment. It aims to enroll 20 participants to find the recommended dose and then assess how well the treatment works.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety and side effects will be measured throughout the study, which is an average of 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Courtney DiNardo, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Safety and Adverse Events (AEs)Through study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0